intravenously 30 h after intravenous inoculation of Y. enterocolitica WA. In vivo efficacy was measured by counting the viable bacteria recovered from the whole spleens of mice sacrificed at selected times. Doxycycline and gentamicin were active in stopping bacterial proliferation. Cefotaxime and imipenem, even at high doses (250 and 100 mg/kg of body weight, respectively), were totally ineffective, as was amoxycillin. Bacterial inocula (107), recovered from either the in vitro growth or the infected spleens, were plated on cefotaxime or imipenem concentration gradients in agar; no emergence of i-lactam-resistant organisms was detected. Based on these experiments it is not possible to explain, from any given property of the antibiotic, the bacteria, or the host, the discrepancy between the in vivo and in vitro activities of cefotaxime and imipenem. On the basis of these results, the use of newer l8-lactam antibiotics should be delayed in the therapy of human Y. enterocolitica infections until further investigations are carried out.
The worldwide distribution of Yersinia enterocolitica and the life-threatening prognosis of septicemia due to this species in compromised hosts (24, 28, 32, 34 ) make investigations into the activity of new antibiotics mandatory. Y. enterocolitica appears to be susceptible to a wide range of antibiotics, especially aminoglycosides and tetracyclines, but the entire species exhibits some degree of resistance to ampicillin, cephalothin, and related ,B-lactam antibiotics because of the synthesis of P-lactamases (5, 6, 11, 13, 15, 16, 31, 40) .
Marked in vitro activity against Y. enterocolitica of newer ,B-lactam antibiotics has been reported (15, 25, 33, 35, 39 -70°C. It was sensitive in vitro to all the antibiotics except the older P-lactams (ICS disk method). The presence of two types of 1-lactamase was detected as initially reported (13) . Inocula were checked to ensure that the plasmid-encoded properties were present, i.e., Ca2l dependency (27) and autoagglutination (19) , prior to injection of mice. Under these culture conditions the virulence of the strain was stable. It induced, after intravenous (i.v.) injection of standardized inocula into mice, a systemic infection of the reticuloendothelial system with reproducible growth kinetics.
Infection of mice. Swiss pathogen-free female mice, aged 5 weeks and weighing 22 ± 2 g at the beginning of each experiment, were purchased from the Ferme Experimentale de Rennemoulin, Institut Pasteur, 78 Villepreux, France. Groups of five mice were injected i.v. with bacterial suspensions in sterile nonpyrogenic saline, adjusted at doses ranging from 1.3 x 106 to 2.4 x 106 CFU to ensure the induction of a reproducible systemic infection.
Antibiotics. The five antibiotics of known potency used in this study were kindly supplied by the manufacturers (or their subsidiary agents in France): amnoxycillin (Beecham, Paris), gentamicin (Unilabo, Levallois-Perret), doxycycline (Pfizer, Paris), cefotaxime (Roussel, Romainville), and imipenem (Merck, Paris).
In vitro susceptibility tests. A strain of Escherichia coli (ATCC 25922) and two strains of Y. enterocolitica (no. 59, serovar 03, and no. 74, serovar 08 [13] ) were checked as quality controls with each antibiotic in each experiment. The media used were Mueller-Hinton broth and agar (Diagnostics Pasteur).
The MICs were determined by the broth macrotiter system and an agar plate dilution method with a multipoint inoculator (Denley Instruments Ltd., Billinghurst, England) as described previously (20) . The final antibiotic concentrations ranged from 0.016 to 512 pLg/ml. Inocula of 1 x 109, 1 x Bacterial counts and expression of results. Viable bacteria, either in the inocula or recovered from spleen homogenates, were counted as CFU on TCS incubated for 18 h at 25°C as described previously (1, 2) . The times we selected for in vivo bacterial growth measurements were based on preliminary experiments that typically showed an early log phase of 6 h, followed by an exponential phase reaching a plateau at 54 h and leading to the death of the mice between 78 and 96 h. Data were obtained for the whole spleens without regard to the size increase of this target organ (1, 4) . The geometric mean and the standard error of the mean were calculated from the data obtained for each group of five mice. In vivo growth curves expressed these results.
At the same time that the spleens were removed, blood samples were collected by retro-orbital puncture.
Detection of antibiotic-resistant bacteria. To check whether any resistant mutants might have been selected by antibiotics during the infection, we sampled the bacteria recovered from the spleens at 78 h postinfection. Spleen homogenates (0.1 ml in saline, 107 CFU) were plated on cefotaxime or imipenem concentration gradients (from 0 to 500 ,ug/ml) in agar (36) and on twofold dilutions ranging from 0.3 to 50 ,ug/ml in agar. Bacteria recovered from the in vitro growth were tested in the same manner.
,-Lactamase production was tested as previously described (13) .
RESULTS
In vitro susceptibility tests. MICs and MBCs were determined in both broth and agar; however, the MICs with inocula of 109 CFU/ml were determined only on agar. MICs in broth were equal to or only one dilution different from MICs in agar. We observed a slight inoculum effect on the MICs: the increase was no more than three dilution factors (log2) ( Table 1) . A significant inoculum effect on the MBCs appeared for 108 and 109 CFU/ml with all antibiotics (six or more log2 increase, except doxycycline, four log2).
Taking into account the MICs, all the drugs were active except amoxycillin. The MBC/MIC ratio (values expressed in log2) with 106 and 107 CFU/ml was equal to 1 or 2 for imipenem, 3 for gentamicin, 4 for cefotaxime and amoxycillin, and 5 or 7 for doxycycline.
In vivo antibiotic activities. Typical activities of the five antibiotics injected at the highest dose are illustrated in Fig.   1 No change in ,B-lactamase production was detected.
DISCUSSION
In the present study, we selected a reproducible mouse model of systemic infection with a highly virulent strain (4) representative of the majority of the Y. enterocolitica strains isolated in human pathology in the United States (17) . We observed that cefotaxime or imipenem, injected i.v. during the phase of irreversible establishment of the septicemic process, even at high doses of 250 and 100 mg/kg of body weight, respectively, were totally ineffective. In contrast, a single injection of gentamicin or doxycycline expressed the activities revealed in vitro in the infected mice effectively. The inefficacy of cefotaxime was confirmed in two experiments in which infected mice received three repeated i.v. injections of this antibiotic at 25 mg/kg, a dose highly effective on other enterobacteria (18) .
Several possibilities may be considered to explain the discrepancies between the antibacterial activities of cefotaxime and imipenem in vitro and in the animal model. The in vitro susceptibility of Y. enterocolitica WA to cefotaxime or imipenem appeared to be at least as great as to the classically active gentamicin and doxycycline. Although the MBC/MIC ratio of cefotaxime was quite high, the MBC/MIC ratio of imipenem was quite compatible with a bactericidal mechanism. Moreover, no P-lactam-resistant mutants were selected by antibiotics during the murine infection even if bacteriological mechanisms could be implied, such as induction of 3-lactamases or changes in outer membrane permeability or in affinity with penicillin-binding proteins (7, 14, 29, 30, 37, 38) .
In experiments on murine systemic infections due to different enterobacteria (18, 21, 23) , the 50% effective doses were obtained with doses of cefotaxime or imipenem lower than those we used. Imipenem, which is hydrolyzed by renal enzyme, is active in systemic infections (18, 23) . However, Lh. host factors that may influence antibiotic activity in the spleen, such as tissue enzyme or pH, were not measured in our experiments and should be planned for future ones.
One could argue that P-lactam antibiotics are poorly endocytosed and thus are mainly effective against extracellular bacterial cells (10) and that pathogenic yersiniae for the most part replicate intracellularly (1, 2, 4) . However, gentamicin, whose action is mainly extracellular (10) , administered at a moderate dose of 20 mg/kg of body weight, was effective in stopping bacterial proliferation in the host. A high dose of doxycycline (125 mg/kg), a drug which has intracellular activity, had the same result.
Pathogenic yersiniae are known to undergo phenotypic variations, depending on the expression of plasmid genes coding for structural changes in the outer membrane proteins (9, 12, 27) . Most of these phenotypic changes are expressed in vivo but not on standard culture media (22) . They are implied in the resistance to host defenses, but further studies would be needed to clarify their possible role in the susceptibility of virulent yersiniae to antimicrobial agents.
We studied only a single isolate of Y. enterocolitica. Even though the WA strain has a phenotype representative of prominent human isolates in the United States (17), we cannot determine that all cases of human septicemia due to Y. enterocolitica are resistant to chemotherapy with cefotaxime or imipenem.
However, on the basis of the conclusions we came to here, it would be wise to delay the use of these newer 3-lactam antibiotics in the therapy of human Y. enterocolitica infections, even if they appear highly active on cultures, until further investigations into their failure in the infected host are carried out.
